Clinical trials & research studies
There are 50 clinical trials and research studies matching liver cancer near you. Last updated 2026-11-14.
Research outlook What's coming for Liver cancer: the next 6 months to 5 yearsData from ClinicalTrials.gov and NIH RePORTER. Last reviewed 2026-11-14 by the Find a Trial editorial team.
Describe your situation. We find matching studies and explain them in plain English.
How it works
Write it the way you'd tell a friend: the diagnosis, how far along it is, what treatments you've had. No medical codes needed.
AI reads each study's rules for who can join, ranks the ones that fit you, and rewrites them in plain English: what's being tested and who it's for.
Every match links to the study's official listing and its contact person. Take it to your doctor and ask the team about pre-screening.
What we search
Most trial finders only show clinical trials. We also include early research the NIH is funding, which can point to what's coming next. Use the Show buttons to pick one or both.
New drugs, devices, therapies and procedures. Many are enrolling patients now. Source: ClinicalTrials.gov.
Lab and population studies funded by the NIH. Most don't enroll patients, but some labs look for volunteers. Source: NIH RePORTER.
Not sure what to type?
Questions
Yes. There's no account, no sign-up and nothing to pay. We don't run any of the studies; we help you find them.
Not unless you ask. You can choose to get email updates about a study; otherwise we never ask for your name, email or phone number. You decide whether to contact a study team, using the details on each listing.
Your diagnosis plus anything that affects who can join: the stage or type, treatments you've had, other conditions, and your age. Leave out your name and contact details.
Open a match and contact the study team listed there. They'll ask a few screening questions to check if you qualify. Pre-screening is free and doesn't commit you to anything. It's a good idea to talk it over with your doctor too.
No. We help you find and understand studies. Your doctor and the study team decide whether a study is right for you.
Fudan University · NCT07147101
We will try different first-line immunotherapy combinations to see which works best for people with advanced hepatocellular carcinoma.
Why this is a good match: First-line immunotherapy combinations for advanced HCC
Conditions: Advanced Hepatocellular Carcinoma
PHASE2 · Peking University Cancer Hospital & Institute · NCT06360042
This study is testing three different combinations of immune and anti-cancer treatments to see which one works best for people with advanced liver cancer that can't be surgically removed.
Why this is a good match: Tests three immuno/anticancer combos for unresectable advanced HCC
Conditions: Unresectable Hepatocellular Carcinoma
PHASE1; PHASE2 · Bristol-Myers Squibb · NCT07291076
This trial will test whether pumitamig, alone or combined with ipilimumab, is safe and tolerable for people with advanced or unresectable hepatocellular carcinoma who have not had prior systemic therapy.
Why this is a good match: Pumitamig ± ipilimumab for untreated advanced unresectable HCC
Conditions: Hepatocellular Carcinoma, First line HCC, Unresectable HCC, Ipilimumab, Pumitamig
PHASE2 · Fudan University · NCT07047586
This trial will test whether adding the immunotherapy tislelizumab to lenvatinib works better than lenvatinib alone for people with advanced liver cancer who progressed after prior PD‑1/PD‑L1 plus bevacizumab treatment.
Why this is a good match: Adds tislelizumab to lenvatinib after progression on prior regimen
Conditions: Hepatocellular Carcinoma
PHASE3 · West China Hospital · NCT05738616
This study is testing a new combination treatment of lenvatinib, TACE, and camrelizumab to see if it helps people with advanced liver cancer live longer compared to using lenvatinib and TACE alone.
Why this is a good match: Lenvatinib plus TACE plus camrelizumab versus lenvatinib+TACE
Conditions: Advanced Hepatocellular Carcinoma, Conversion resection, Lenvatinib, Transcatheter arterial chemoembolization, Camrelizumab
PHASE3 · Sun Yat-sen University · NCT07594340
This trial tests whether FOLFOX-HAIC plus immunotherapy and anti-angiogenic therapy works better than TACE plus the same systemic therapy for adults with intermediate-stage hepatocellular carcinoma with tumors beyond Up-To-Seven criteria.
Why this is a good match: FOLFOX-HAIC plus immunotherapy and anti-angiogenic therapy for intermediate HCC
Conditions: Hepatocellular Carcinoma, hepatocellular carcinoma
PHASE1 · Abramson Cancer Center at Penn Medicine · NCT05488522
This study is testing a new treatment that combines radiation therapy with immunotherapy drugs to see if it can help people with advanced liver cancer who can't have surgery.
Why this is a good match: Combines radiation therapy with immunotherapy for unresectable advanced HCC
Conditions: Hepatocellular Carcinoma
Fujian Provincial Hospital · NCT06602011
This study is testing a new combination treatment for people with advanced liver cancer that has spread to the bile ducts to see if it can help them when surgery isn't an option.
Why this is a good match: New combination for HCC with bile duct involvement
Conditions: Hepatocellular Carcinoma, Hepatocellular carcinoma, bile duct tumor thrombus, TACE, Lenvatinib
PHASE2 · Fudan University · NCT07536789
This study will test whether Becotatug vedotin (MRG003) helps people with advanced hepatocellular carcinoma whose cancer progressed after PD‑1/L1 therapy.
Why this is a good match: Becotatug vedotin for HCC after progression on PD‑1/L1 therapy
Conditions: Hepato Cellular Carcinoma
PHASE1; PHASE2 · Pfizer · NCT07227012
This tests PF-08634404 by itself and together with ipilimumab in adults whose hepatocellular carcinoma is advanced and cannot be removed surgically.
Why this is a good match: PF-08634404 alone and with ipilimumab for advanced HCC
Conditions: Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms
PHASE1 · Tongji Hospital · NCT06470256
This study is testing whether combining surgery with targeted therapy and immunotherapy can help people with advanced liver cancer live longer and feel better.
Why this is a good match: Combines surgery, targeted therapy, and immunotherapy to improve outcomes
Conditions: Advanced Hepatocellular Carcinoma, HCC, Palliative Hepatectomy, Immunotherapy, Targeted therapy
Guangxi Medical University · NCT06405321
This study is testing different treatment combinations for liver cancer to see which ones work best and help patients live longer.
Why this is a good match: Evaluates multiple treatment combinations to identify optimal therapy
Conditions: Hepatocellular Carcinoma, conversion therapy, neoadjuvant therapy
NA · Sun Yat-sen University · NCT06550921
This study is testing if combining a targeted treatment with a special type of therapy can help people with advanced liver cancer that has spread a little, to see if it improves their chances of living longer.
Why this is a good match: Combines targeted therapy with novel modality for limited metastatic HCC
Conditions: Advanced Hepatocellular Carcinoma, Oligometastasis, Ablation, Anti-PD1 Antibody, Lenvatinib
PHASE1 · Alnylam Pharmaceuticals · NCT06600321
This study is testing a new treatment called ALN-BCAT, alone and with another drug, to see if it can safely help people with advanced liver cancer.
Why this is a good match: Tests ALN-BCAT alone and in combination for advanced HCC
Conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Hepatocellular carcinoma, Pembrolizumab, CTNNB1
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · NCT07365930
This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.
Why this is a good match: Evaluates TIPS impact for patients on Tecentriq plus Avastin
Conditions: Hepatocellular Carcinoma, HCC, TIPS, Tecentriq, Avastin
Sun Yat-sen University · NCT06641713
This study is testing whether a new way of giving chemotherapy directly to the liver works better than a standard method for people with large liver cancer.
Why this is a good match: Compares novel intra-arterial chemotherapy delivery to standard method
Conditions: Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Advanced hepatocellular carcinoma, TACE
NA · Zhongda Hospital · NCT06909708
This study is testing whether a new treatment using yttrium-90 carbon microspheres works better than the standard chemoembolization for people with advanced liver cancer.
Why this is a good match: Yttrium-90 carbon microspheres versus standard chemoembolization
Conditions: Unresectable Hepatocellular Carcinoma, HCC, TACE, Selective internal radiation therapy, Yttrium-90
NA · Ochsner Health System · NCT05953961
This study is testing which treatment, either 90-Yttrium Therasphere or microwave ablation, works better for people with small liver cancer and low albumin levels to see which one helps keep the cancer from getting worse in the first year.
Why this is a good match: 90-Y Therasphere versus microwave ablation for small tumors low albumin
Conditions: Carcinoma, Hepatocellular, Yttrium-90, Hypoalbuminemia
NA · Sun Yat-sen University · NCT06740370
This study is testing a new treatment that combines a special type of chemotherapy with Lenvatinib and PD-1 inhibitors to see if it can help patients with serious liver cancer that has ruptured.
Why this is a good match: Combines specialized chemotherapy with lenvatinib and PD-1 inhibitors for ruptured HCC
Conditions: Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody, Lenvatinib, ruptured hepatocellular carcinoma
PHASE2 · Sun Yat-sen University · NCT05751343
This study is testing whether a new treatment that combines a type of chemotherapy with two immunotherapy drugs can help people with liver cancer that can't be surgically removed feel better compared to current treatments.
Why this is a good match: Chemo combined with two immunotherapies for unresectable HCC symptom benefit
Conditions: Hepatocellular Carcinoma
